×

Type 2 helper T cell-selective immune response suppressors

  • US 6,376,501 B1
  • Filed: 06/21/2000
  • Issued: 04/23/2002
  • Est. Priority Date: 12/22/1997
  • Status: Expired due to Fees
First Claim
Patent Images

1. A method of inhibiting a type 2 helper T cell-selective immune response in a subject in need thereof, comprising administering to the subject a composition comprising a purine derivative represented by General Formula (I) embedded imagewhereinR2 is hydrogen or a C1-14 hydrocarbon in which —

  • CH2

    not directly bound to the purine skeleton and CH2 in —

    CH3 not directly bound to the purine skeleton may be substituted by carbonyl, sulfonyl, —

    O—

    or —

    S—

    ;



    CH2 may be substituted by ═

    O or ═

    S;

    C—

    H in CH2

    not directly bound to the purine skeleton, C—

    H in —

    CH3 not directly bound to the purine skeleton, C—

    H in >

    CH—

    not directly bound to the purine skeleton, C—

    H in ═

    CH—

    not directly bound to the purine skelton and C—

    H in ═

    CH2 may be substituted by N, C-halogen or C—

    CN;

    R6 is hydroxyl, amino or amino which is mono- or di-substituted by a C1-10 hydrocarbon group(s);

    R8 is hydroxyl, mercapto, C1-18 acyloxy or C1-19 hydrocarbon group-substituting oxycarbonyloxy; and

    R9 is a C1-14 hydrocarbon group in which —

    CH2

    not directly bound to the purine skeleton and CH2 in —

    CH3 not directly bound to the purine skeleton may be substituted by carbonyl, sulfonyl, —

    O—

    or —

    S—

    ;



    CH2 may be substituted by ═

    O or ═

    S;

    C—

    H in —

    CH2

    not directly bound to the purine skeleton, C—

    H in —

    CH3 not directly bound to the purine skeleton, C—

    H in >

    CH—

    not directly bound to the purine skeleton, C—

    H in ═

    CH—

    not directly bound to the purine skeleton, C—

    H in ═

    CH2 and C—

    H in ≡

    CH may be substituted by N, C-halogen or C—

    CN;

    or its tautomer or a pharmaceutically acceptable salt of the purine derivative or the tautomer to inhibit a type 2-helper T cell-selective immune response.

View all claims
  • 3 Assignments
Timeline View
Assignment View
    ×
    ×